Medical Education

WEBINAR SUMMARY:

This foundational webinar will clarify the science and clinical role of blood-based biomarkers (BBMs) in Alzheimer’s disease (AD). Analytical and clinical performance of AD BBM tests and appropriate positioning of testing within recommended diagnostic pathways alongside cognitive assessment, rule-out labs, and other testing modalities (PET/CSF) will be discussed. Special emphasis will be placed on interpreting positive, indeterminate, and negative test results. Included is a case-based dialogue to address common myths, patient communication tips, and how BBMs enable earlier access to specialist care and potential disease-modifying therapies.

SPEAKER:

Zivjena Vucetic, MD, PhD
Adjunct Assistant Professor
College of Science & Technology, Department of Biology, Temple University

OBJECTIVES:

• Differentiate AD BBM tests and key performance characteristics for amyloid pathology detection.
• Identify appropriate clinical use scenarios to order AD BBM tests within a structured diagnostic workup.
• Compare AD BBM tests to PET and CSF for amyloid/tau confirmation.
• Interpret positive, negative and indeterminate test results to guide patient management and patient/caregiver consultations.

ACCREDIATIONS:

• Continuing education credit: One P.A.C.E.® credit-hour will be provided for this complimentary basic level program. Fujirebio is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.
• This program is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563
• Certificate of Attendance is available for all attendees. 

REGISTER NOW

WEBINAR SUMMARY:

The advent of disease-modifying therapies (DMTs) has significantly altered the treatment of Alzheimer’s disease (AD), making timely and accurate diagnosis essential for optimal management. Detecting AD pathology with imaging and fluid biomarkers is critical for identifying patients eligible for these newer therapies. As the fluid biomarker landscape evolves to include blood-based biomarkers alongside cerebrospinal fluid (CSF) testing, clinicians face challenges in integrating these tools into clinical practice. This case-based educational activity aims to equip health care professionals with the knowledge and confidence to appropriately and effectively apply fluid biomarker testing to facilitate early diagnosis and improve the management of patients with early symptomatic AD.

SPEAKER:

Pierre N. Tariot, MD
Banner Alzheimer’s Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
Phoenix, AZ

OBJECTIVES:

• Assess the advantages, limitations, and best practices for the use of CSF biomarkers in the early and accurate diagnosis of AD
• Discuss blood-based biomarkers for AD and their evolving role in research and clinical practice
• Incorporate into clinical practice evidence-based recommendations for the use of AD fluid biomarker testing to support early identification and guide the personalized management of early AD with DMTs

ACCREDIATIONS:

• Physician Credit: up to 1.0 AMA PRA Category 1 Credits™,
• Nursing Credit: up to 1.0 ANCC Nursing Contact Hours,
• Physician Assistant Credit: up to 1.0 AAPA Category 1 CME Credit,
• Maintenance of Certification Credit: up to 1.0 MOC point in the ABIM MOC program

Expires: December 16, 2025

LEARN NOW